PHARMA SECTOR THINKS HARD OVER UPCOMING EU REFORM OF ORPHAN MEDICINE CONTROLS
May 1st, 2016
Important changes in the way that the European Union (EU) deals with orphan medicines could be signalled later this year when the European Commission publishes a revised version of its 2003 Communication (policy paper) on the topic. The Commission has said wants to "streamline the regulatory framework” underpinning the assistance given to manufacturers of orphan drugs and to adapt the policy to “technical progress", and asked for comments from the pharma industry and other interested parties on how it should proceed.
In its preliminary text put out for ...
Full access to this article can be arranged with permission from the client that first ordered it. Please contact us to request access. Entries are uploaded to our archive at least one year after being published by a client – free access is restricted to International News Services journalists for background research only. The article date indicates when copy was filed to a client, not when posted to this archive. Upon client requests, International News Services will remove such articles from the archive or not upload them in the first place. They are included to demonstrate the breadth of topics undertaken by the agency and also to help promote clients’ coverage.